Effects of omentin on flap viability: an experimental research on rats.

Viability decreases at the distal parts with an increase in the length of flaps. In this study, we evaluated the effects of subcutaneously administered omentin on flap viability, where it is applied to distal one-third part of McFarlane flaps elevated from the rat's dorsal skin. Twenty-four adult, female, Sprague-Dawley rats were used. Subjects were divided into three groups; group 1 is the control group, group 2 received omentin 1 week before flap elevation, and group 3 received omentin 2 d before and at the day of flap elevation. About 1 cc (300 nanogram/cc) omentin applied by subcutaneous injections to the distal one-third flap. Photos are taken daily for macroscopic evaluations. The 3-mm full thickness punch biopsies at the third day and 1-cm biopsies at the seventh day from the middle of the one-third distal third of the flaps were taken. Necrotic and viable areas were measured. Neutrophil counting, epidermis thickness, inflammation, edema, and vascular endothelial growth factor (VEGF) immune staining were evaluated using histopathological analyses. Endothelial Nitric Oxide Synthase (eNOS) expression was performed by ELISA. Omentin increased the percentage of the viable areas of flaps, epidermal thickness, number of newly formed blood vessels, and eNOS expression levels. The results showed statistical significance. Omentin human increases the viable areas of flaps and may be used for enhancement of flap survival.